12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights 1 hour ago
Movers
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their outstanding shares is
Gainers
- Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session.
- ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their outstanding shares is at $6.4 million.
- SL Science Holding (NASDAQ:SLBT) stock rose 10.74% to $0.8. The company's market cap stands at $405.0 million.
- Can Fite Biopharma (AMEX:CANF) stock increased by 10.32% to $1.71. The company's market cap stands at $3.3 million.
- Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 10.0% to $0.4. The company's market cap stands at $3.2 million.
- Streamex (NASDAQ:STEX) stock rose 8.98% to $0.36. The company's market cap stands at $38.3 million. As per the news, the Q3 earnings report came out today.
Losers
- Basel Medical Group (NASDAQ:BMGL) shares fell 24.0% to $0.52 during Thursday's pre-market session. The market value of their outstanding shares is at $9.2 million.
- Beyond Air (NASDAQ:XAIR) shares declined by 23.96% to $2.0. The company's market cap stands at $2.5 million. As per the news, the Q2 earnings report came out yesterday.
- OptimizeRx (NASDAQ:OPRX) shares decreased by 20.9% to $7.08. The company's market cap stands at $165.5 million. As per the news, the Q3 earnings report came out yesterday.
- Xenetic Biosciences (NASDAQ:XBIO) shares declined by 16.41% to $1.56. The company's market cap stands at $4.3 million.
- Co-Diagnostics (NASDAQ:CODX) stock decreased by 12.32% to $0.24. The market value of their outstanding shares is at $2.4 million. As per the press release, Q3 earnings came out 2 days ago.
- Bone Biologics (NASDAQ:BBLG) stock fell 9.86% to $0.32. The company's market cap stands at $1.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
